A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2012
At a glance
- Drugs MGL-3196 (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
- 06 Nov 2012 Results have been presented at the American Heart Association 2012 Scientific Sessions according to a Madrigal Pharmaceuticals media release. Results were also summarised in th media release.
- 18 Jan 2012 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History